地図状萎縮症の世界市場レポート 2025年

地図状萎縮症市場規模は、今後数年で急成長が見込まれます。2029年には年間平均成長率（CAGR）13.5%で35億米ドルに成長します。予測期間中に予想される成長は、研究開発への注目の高まり、研究開発投資の増加、スマートフォンの利用拡大、ヘルスケア支出の増加、臨床検査への投資の増加などの要因によるものと考えられます。予測期間における主要動向としては、遺伝子治療の進展、ヘルスケア技術の進歩、新技術の開発、遠隔医療の採用拡大、革新的で効果的な薬剤の創出などが挙げられます。

加齢黄斑変性症（AMD）の有病率の増加が地図状萎縮症市場の成長を牽引すると予想されます。AMDは、高齢者の網膜中心部が損傷し、細かい部分が見えにくくなる眼の疾患です。人口の高齢化がAMD患者の増加の主要因であり、より多くの人々が長生きするようになり、自然な老化プロセスが徐々に目の損傷をもたらし、時間の経過とともに個人がこの病気にかかりやすくなります。地図状萎縮症の治療は、網膜障害の進行を遅らせ、残存視力を維持することで、AMD患者をサポートします。例えば、2024年1月のMedical News Todayのレポートによると、加齢黄斑変性の世界の症例数は、2040年までに1億9,600万人から2億8,800万人に増加すると予測されています。このように、AMDの有病率の増加が地図状萎縮症市場を前進させています。

地図状萎縮症市場の各社は、この疾患の先進的な治療法を開発するため、補体阻害剤治療などの革新的な治療にますます力を注いでいます。補体阻害療法は、特定の疾患に関連する過剰な免疫反応を抑制し、健康な細胞を損傷から守り、疾患の進行を抑制します。2025年2月、日本の製薬会社であるアステラス製薬は、同社の医薬品であるIZERVAYが、AMDに続発する地図状萎縮症の治療として米国食品医薬品局（FDA）から承認されたと発表しました。今回の承認により、イゼルベイは投与期間の制限なく使用できるようになり、地図状萎縮症の管理に柔軟性をもたらし、患者とヘルスケアプロバイダの双方に長期治療の選択肢を提供することになります。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場-マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の地図状萎縮症PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の地図状萎縮症市場：成長率分析
• 世界の地図状萎縮症市場の実績：規模と成長、2019～2024年
• 世界の地図状萎縮症市場の予測：規模と成長、2024～2029年、2034年
• 世界の地図状萎縮症総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の地図状萎縮症市場：薬剤タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 抗血管内皮増殖因子（VEGF）療法
• 補体阻害剤
• 神経保護剤
• その他
• 世界の地図状萎縮症市場：診断別、実績と予測、2019～2024年、2024～2029年、2034年
• 眼底自己蛍光（FAF）
• 光干渉断層撮影血管造影（OCT-A）
• 多焦点網膜電図（mfERG）
• 世界の地図状萎縮症市場：投与経路別、実績と予測、2019～2024年、2024～2029年、2034年
• 硝子体内
• 経口
• その他
• 世界の地図状萎縮症市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院薬局
• 小売薬局
• オンライン薬局
• その他
• 世界の地図状萎縮症市場、抗血管内皮増殖因子（VEGF）療法のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• ラニビズマブ
• アフリベルセプト
• ベバシズマブ
• 世界の地図状萎縮症市場、補体阻害剤のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• ペグセタコプラン
• LFG316
• 世界の地図状萎縮症市場、神経保護剤のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• ラタノプロスト
• ブリモニジン
• 世界の地図状萎縮症市場、その他の医薬品のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• ステロイド
• レチノイド
• 併用療法

第7章 地域別・国別分析

• 世界の地図状萎縮症市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の地図状萎縮症市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 地図状萎縮症市場：競合情勢
• 地図状萎縮症市場：企業プロファイル
  • Regeneron Pharmaceuticals Inc.
  • Boehringer Ingelheim
  • Astellas Pharma Inc.
  • Biogen Inc.
  • Ocugen Inc.

第31章 その他の大手企業と革新的企業

• Kodiak Sciences Inc.
• Apellis Pharmaceuticals Inc.
• NGM Biopharmaceuticals Inc.
• Voyager Therapeutics
• Kriya Therapeutics
• Stealth BioTherapeutics
• Kiora Pharmaceuticals
• Iveric Bio
• Alkeus Pharmaceuticals
• Nanoscope Therapeutics
• Graybug Vision
• SparingVision
• 4D Molecular Therapeutics
• Clearside Biomedical
• Gensight Biologics

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、戦略

• 地図状萎縮症市場、2029年：新たな機会を提供する国
• 地図状萎縮症市場、2029年：新たな機会を提供するセグメント
• 地図状萎縮症市場、2029年：成長戦略
  • 市場動向による戦略
  • 競合の戦略

第36章 付録

Geographic atrophy is an eye condition that causes gradual vision loss due to damage to the retina. It is a severe form of age-related macular degeneration (AMD) that results in blind spots in central vision.

The primary drug treatments for geographic atrophy include anti-vascular endothelial growth factor (VEGF) therapy, complement inhibitors, neuroprotective agents, and others. Complement inhibitors work by regulating an overactive immune response, blocking specific proteins that contribute to inflammation and cell damage. Diagnosis is typically performed using techniques such as fundus autofluorescence (FAF), optical coherence tomography angiography (OCT-A), and multifocal electroretinography (mfERG). These treatments are administered through various routes, such as intravitreal, oral, and others, and are distributed through various channels, including hospital pharmacies, retail pharmacies, online pharmacies, and others.

The geographic atrophy market research report is one of a series of new reports from The Business Research Company that provides geographic atrophy market statistics, including the geographic atrophy industry global market size, regional shares, competitors with the geographic atrophy market share, detailed geographic atrophy market segments, market trends, and opportunities, and any further data you may need to thrive in the geographic atrophy industry. This geographic atrophy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The geographic atrophy market size has grown rapidly in recent years. It will grow from $1.86 billion in 2024 to $2.12 billion in 2025 at a compound annual growth rate (CAGR) of 13.7%. The growth observed in the historic period can be attributed to factors such as the growing geriatric population, rising demand for effective treatment options, increasing prevalence of geographic atrophy, greater health awareness, and a rise in the incidence of retinal diseases.

The geographic atrophy market size is expected to see rapid growth in the next few years. It will grow to $3.50 billion in 2029 at a compound annual growth rate (CAGR) of 13.5%. The growth expected during the forecast period can be attributed to factors such as a rising focus on research and development, increased R&D investments, the growing use of smartphones, higher healthcare expenditure, and more investment in clinical trials. Key trends in the forecast period include advancements in gene therapy, progress in healthcare technology, the development of new technologies, greater adoption of telemedicine, and the creation of innovative and effective drugs.

The increasing prevalence of age-related macular degeneration (AMD) is expected to drive the growth of the geographic atrophy market. AMD is an eye condition that damages the central part of the retina in older adults, making it difficult to see fine details. The aging population is the primary factor contributing to the rise in AMD cases, as more people are living longer, and the natural aging process leads to gradual eye damage, making individuals more susceptible to the disease over time. Treatments for geographic atrophy support AMD patients by slowing the progression of retinal damage and preserving remaining vision. For example, a report from Medical News Today in January 2024 highlighted that global cases of age-related macular degeneration are projected to increase from 196 million to 288 million by 2040. Thus, the growing prevalence of AMD is driving the geographic atrophy market forward.

Companies in the geographic atrophy market are increasingly focusing on innovative therapies, such as complement inhibitor therapy, to develop advanced treatments for the condition. Complement inhibitor therapy helps slow an overactive immune response associated with certain diseases, protecting healthy cells from damage and reducing disease progression. In February 2025, Astellas Pharma Inc., a Japan-based pharmaceutical company, announced that its drug IZERVAY (avacincaptad pegol intravitreal solution) was approved by the Food and Drug Administration (FDA) for treating geographic atrophy secondary to AMD. This approval allows for the use of IZERVAY without limitations on the duration of dosing, providing greater flexibility in managing geographic atrophy and offering long-term treatment options for both patients and healthcare providers.

In January 2025, Bausch + Lomb Corporation, a US-based pharmaceutical and medical device company specializing in eye health products, acquired Whitecap Biosciences LLC for an undisclosed amount. This acquisition aims to expand Bausch + Lomb's portfolio of innovative eye health solutions by integrating Whitecap Biosciences' expertise in advanced ocular therapeutics. Whitecap Biosciences, a US-based pharmaceutical company, is focused on developing novel therapies for ophthalmic diseases, including geographic atrophy.

Major players in the geographic atrophy market are Regeneron Pharmaceuticals Inc., Boehringer Ingelheim, Astellas Pharma Inc., Biogen Inc., Ocugen Inc., Kodiak Sciences Inc., Apellis Pharmaceuticals Inc., NGM Biopharmaceuticals Inc., Voyager Therapeutics, Kriya Therapeutics, Stealth BioTherapeutics, Kiora Pharmaceuticals, Iveric Bio, Alkeus Pharmaceuticals, Nanoscope Therapeutics, Graybug Vision, SparingVision, 4D Molecular Therapeutics, Clearside Biomedical, Gensight Biologics.

North America was the largest region in the geographic atrophy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in geographic atrophy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the geographic atrophy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The geographic atrophy market consists of revenues earned by entities by providing gene therapies, and stem cell therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The geographic atrophy market also includes sales of artificial retinas, and medication. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Geographic Atrophy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on geographic atrophy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for geographic atrophy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The geographic atrophy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: Anti-Vascular Endothelial Growth Factor (VEGF) Therapy; Complement Inhibitors; Neuroprotective Agents; Other Drugs
• 2) By Diagnosis: Fundus Autofluorescence (FAF); Optical Coherence Tomography Angiography (OCT-A); Multifocal Electroretinography (mfERG)
• 3) By Route Of Administration: Intravitreal; Oral; Other Routes Of Administration
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Distribution Channels
• Sub Segments:
• 1) By Anti-Vascular Endothelial Growth Factor (VEGF) Therapy: Ranibizumab; Aflibercept; Bevacizumab
• 2) By Complement Inhibitors: Pegcetacoplan; Lfg316
• 3) By Neuroprotective Agents: Latanoprost; Brimonidine
• 4) By Other Drugs: Steroids; Retinoids; Combination Therapy
• Companies Mentioned: Regeneron Pharmaceuticals Inc.; Boehringer Ingelheim; Astellas Pharma Inc.; Biogen Inc.; Ocugen Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Geographic Atrophy Market Characteristics

3. Geographic Atrophy Market Trends And Strategies

4. Geographic Atrophy Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Geographic Atrophy Growth Analysis And Strategic Analysis Framework

• 5.1. Global Geographic Atrophy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Geographic Atrophy Market Growth Rate Analysis
• 5.4. Global Geographic Atrophy Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Geographic Atrophy Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Geographic Atrophy Total Addressable Market (TAM)

6. Geographic Atrophy Market Segmentation

• 6.1. Global Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Anti-Vascular Endothelial Growth Factor (VEGF) Therapy
• Complement Inhibitors
• Neuroprotective Agents
• Other Drugs
• 6.2. Global Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Fundus Autofluorescence (FAF)
• Optical Coherence Tomography Angiography (OCT-A)
• Multifocal Electroretinography (mfERG)
• 6.3. Global Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intravitreal
• Oral
• Other Routes Of Administration
• 6.4. Global Geographic Atrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Other Distribution Channels
• 6.5. Global Geographic Atrophy Market, Sub-Segmentation Of Anti-Vascular Endothelial Growth Factor (VEGF) Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ranibizumab
• Aflibercept
• Bevacizumab
• 6.6. Global Geographic Atrophy Market, Sub-Segmentation Of Complement Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pegcetacoplan
• Lfg316
• 6.7. Global Geographic Atrophy Market, Sub-Segmentation Of Neuroprotective Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Latanoprost
• Brimonidine
• 6.8. Global Geographic Atrophy Market, Sub-Segmentation Of Other Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Steroids
• Retinoids
• Combination Therapy

7. Geographic Atrophy Market Regional And Country Analysis

• 7.1. Global Geographic Atrophy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Geographic Atrophy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Geographic Atrophy Market

• 8.1. Asia-Pacific Geographic Atrophy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Geographic Atrophy Market

• 9.1. China Geographic Atrophy Market Overview
• 9.2. China Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Geographic Atrophy Market

• 10.1. India Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Geographic Atrophy Market

• 11.1. Japan Geographic Atrophy Market Overview
• 11.2. Japan Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Geographic Atrophy Market

• 12.1. Australia Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Geographic Atrophy Market

• 13.1. Indonesia Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Geographic Atrophy Market

• 14.1. South Korea Geographic Atrophy Market Overview
• 14.2. South Korea Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Geographic Atrophy Market

• 15.1. Western Europe Geographic Atrophy Market Overview
• 15.2. Western Europe Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Geographic Atrophy Market

• 16.1. UK Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Geographic Atrophy Market

• 17.1. Germany Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Geographic Atrophy Market

• 18.1. France Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Geographic Atrophy Market

• 19.1. Italy Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Geographic Atrophy Market

• 20.1. Spain Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Geographic Atrophy Market

• 21.1. Eastern Europe Geographic Atrophy Market Overview
• 21.2. Eastern Europe Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Geographic Atrophy Market

• 22.1. Russia Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Geographic Atrophy Market

• 23.1. North America Geographic Atrophy Market Overview
• 23.2. North America Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Geographic Atrophy Market

• 24.1. USA Geographic Atrophy Market Overview
• 24.2. USA Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Geographic Atrophy Market

• 25.1. Canada Geographic Atrophy Market Overview
• 25.2. Canada Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Geographic Atrophy Market

• 26.1. South America Geographic Atrophy Market Overview
• 26.2. South America Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Geographic Atrophy Market

• 27.1. Brazil Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Geographic Atrophy Market

• 28.1. Middle East Geographic Atrophy Market Overview
• 28.2. Middle East Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Geographic Atrophy Market

• 29.1. Africa Geographic Atrophy Market Overview
• 29.2. Africa Geographic Atrophy Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Geographic Atrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Geographic Atrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Geographic Atrophy Market Competitive Landscape And Company Profiles

• 30.1. Geographic Atrophy Market Competitive Landscape
• 30.2. Geographic Atrophy Market Company Profiles
  • 30.2.1. Regeneron Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Boehringer Ingelheim Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Astellas Pharma Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Biogen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Ocugen Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Geographic Atrophy Market Other Major And Innovative Companies

• 31.1. Kodiak Sciences Inc.
• 31.2. Apellis Pharmaceuticals Inc.
• 31.3. NGM Biopharmaceuticals Inc.
• 31.4. Voyager Therapeutics
• 31.5. Kriya Therapeutics
• 31.6. Stealth BioTherapeutics
• 31.7. Kiora Pharmaceuticals
• 31.8. Iveric Bio
• 31.9. Alkeus Pharmaceuticals
• 31.10. Nanoscope Therapeutics
• 31.11. Graybug Vision
• 31.12. SparingVision
• 31.13. 4D Molecular Therapeutics
• 31.14. Clearside Biomedical
• 31.15. Gensight Biologics

32. Global Geographic Atrophy Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Geographic Atrophy Market

34. Recent Developments In The Geographic Atrophy Market

35. Geographic Atrophy Market High Potential Countries, Segments and Strategies

• 35.1 Geographic Atrophy Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Geographic Atrophy Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Geographic Atrophy Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer